MAIA Biotechnology, Inc. (MAIA)
MAIAAMEXBiotechnology: Pharmaceutical Preparations
$1.06
-0.0300 (-2.75%) today
Regular session, Nov 10, 1:18 PM ET
- Market cap
- $65.45m
- P/E
- –
- EPS, last 4 quarters
- $-0.4700
- Dividend yield
- –
- Day range
- $1.06 to $1.12
- 52-week range
- $0.8700 to $3.19
- Average volume
- –
- Previous close
- $1.09
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $14.00, +1220.8% from here
Earnings
next estimate $-0.1400Next report
Dec 2025
+38.5%
Mar 2026
+22.2%
Jun 2026
-18.2%
Sep 2026
+7.7%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$9.36m | -$4.32m | -$6.95m | -$8.32m |
| Net income | -$8.90m | -$3.63m | -$6.37m | -$7.94m |
News
8 latest- MAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65% RTTNews · Oct 7, 2026
- MAIA Broadens Phase 3 Lung Cancer Study Footprint Across Europe RTTNews · Sep 24, 2026
- MAIA Reaches Enrollment Milestone Of 65 In Phase 3 THIO-104 For Ateganosine In Lung Cancer RTTNews · Sep 22, 2026
- Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA RTTNews · Sep 16, 2026
- MAIA Doses First U.S. Patient In Phase 2 THIO-101 Trial For Advanced Non-Small Cell Lung Cancer RTTNews · Sep 16, 2026
- MAIA Biotechnology Board Member, CEO Buys Shares Amid Phase 3 NSCLC Studies RTTNews · Sep 16, 2026
- MAIA Biotechnology Board Member, CEO Buy Shares Amid Phase 3 NSCLC Studies RTTNews · Sep 16, 2026
- MAIA Biotechnology Presents Ateganosine, Next-Generation Drug Data At IRT 2026 RTTNews · Sep 10, 2026
The company
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.